Ponatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Explore 31 assets in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Alberta
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07301424CT.gov Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | — | Not Yet Recruiting | — | — | — |
NCT07224100CT.gov Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | — | Recruiting | — | — | — |
NCT06175702CT.gov Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | — | Not Yet Recruiting | — | — | — |
NCT04722848CT.gov Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | — | Active Not Recruiting | — | — | — |
NCT04475731CT.gov Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | — | Active Not Recruiting | — | — | — |
NCT03709017CT.gov Iclusig PMS in CML or Ph+ALL Patients | — | Unknown | — | — | — |
NCT03576547CT.gov Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | — | Terminated | — | — | — |
NCT03263572CT.gov Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT01641107CT.gov Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ponatinib (this asset) | University of Alberta | P3 | BB · 65 |
| Nilotinib | The University of Hong Kong | P2 | BBB |
| Blinatumomab | Novartis Pharmaceuticals | P3 | BBB |
| Cytarabine | Novartis Pharmaceuticals | P3 | BBB |
| Imatinib | The University of Hong Kong | P3 | BB |
| Dasatinib | SWOG Cancer Research Network | P3 | BB |
| Olverembatinib | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Methotrexate | Novartis Pharmaceuticals | P3 | BB |
| Prednisone | University of Washington | P3 | BB |
+39 more in the B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) cohort
Other indications for Ponatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Myeloid Leukemia | — | P2 | BB · 66 |
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 65 |
| Acute Lymphoblastic Leukemia | — | P2/3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ponatinib in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ponatinib-b-lymphoblastic-leukemialymphoma-with-t922q341q112
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →